Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | BMS Newsroom

U.S. Food and Drug Administration and European Medicines Agency accept marketing applications for Opdivo in this patient population

Regulatory submissions based on CheckMate -141, in which Opdivo met its primary endpoint of overall survival, compared to investigator’s choice of therapy

Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | BMS Newsroom